Compounders Research Compare

Cibus, Inc.(CBUS)

Biotechnology · San Diego, CA

$1.68-0.03 (-1.75%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Cibus, Inc.

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

San Diego, CA

118 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Craig Wichner

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T13:25:50.756Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:25:50.756Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 128,237,088
Total debt · period ending 2026-06-30: 32,742,000
Cash · period ending 2026-06-30: 20,429,000
TTM operating income · period ending 2026-06-30: -53,942,000

FMP input reference: b7114033928f702054061c44125c31231f02474951b0017c983a2cfe9aac3c1c

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CBUS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

CBUS Competitors' EV/EBIT Ratio

Cibus, Inc.

Current

Market Cap

$128.24M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Entera Bio Ltd.

Market Cap

$129.14M

EV/EBIT Ratio

N/A

TTM Avg

3.95x

3Y Avg

3.95x

5Y Avg

3.95x

Health Catalyst, Inc.

Market Cap

$130.05M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

enGene Holdings Inc.

Market Cap

$125.27M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AirSculpt Technologies, Inc.

Market Cap

$134.74M

EV/EBIT Ratio

N/A

TTM Avg

60.31x

3Y Avg

490.71x

5Y Avg

419.04x

Freenome, Inc.

Market Cap

$137.29M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TuHURA Biosciences, Inc.

Market Cap

$119.09M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BGM Group Ltd.

Market Cap

$118.63M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Insight Molecular Diagnostics Inc.

Market Cap

$118.50M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KORU Medical Systems, Inc.

Market Cap

$138.26M

EV/EBIT Ratio

N/A

TTM Avg

734.52x

3Y Avg

360.78x

5Y Avg

245.93x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Cibus, Inc. (CBUS)	$128.24M	N/A	N/A	N/A	N/A
Entera Bio Ltd. (ENTX)vs ›	$129.14M	N/A	3.95x	3.95x	3.95x
Health Catalyst, Inc. (HCAT)vs ›	$130.05M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$125.27M	N/A	N/A	N/A	N/A
AirSculpt Technologies, Inc. (AIRS)vs ›	$134.74M	N/A	60.31x	490.71x	419.04x
Freenome, Inc. (FRNM)vs ›	$137.29M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$119.09M	N/A	N/A	N/A	N/A
BGM Group Ltd. (BGM)vs ›	$118.63M	N/A	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$118.50M	N/A	N/A	N/A	N/A
KORU Medical Systems, Inc. (KRMD)vs ›	$138.26M	N/A	734.52x	360.78x	245.93x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics